The pandemic is far from displaying indicators of slowing down and there are new worries with fresh surge in situations emerging across distinctive nations, cautions Dr Soumya Swaminathan. The be concerned for the chief scientist at the World Health Organisation (WHO) stems from the reality that the delta variant is becoming dominant all more than the world with 104 nations documenting it as a result far.
TheSpuzz Online reached out to Dr Swaminathan on exactly where we stand on the nevertheless unfolding pandemic and what India demands to be focussed on getting just emerged out of debilitating second wave and with fears of a most likely third wave on the horizon.
“There are new surges emerging in many countries with huge gaps in vaccination coverage that need to be bridged,” she says describing the present stage of the pandemic as “a critical phase not just in India but also in several other countries around the world.” Some regions in India, she says, “like in the North East are seeing an uptick with relatively high test positivity rate, indicating the need for increased testing. Globally also, Covid cases are rising even in countries with high vaccine coverage.”
Dr Swaminathan attributes the present surge to 4 primary motives: “apart from the spreading delta variant, there is increased social mixing, cultural and sporting events; relaxation of public health measures; and insufficient vaccine coverage.”
Journey With The Jabs In India
Specifically for India, she says, “the goal should be to prevent a third wave. Till at least 40 per cent to 50 per cent of the population is fully vaccinated (up from less than 5 percent currently), testing, tracking, isolating cases and individual measures like masking, distancing and focus on good ventilation must continue.” In addition, she feels, “efforts must be made to identify reasons for vaccine hesitancy and address them.”
To these who have seen the images of the Kumbh mela and the Indian election rallies and now the packed Wembley arena images for the Euro cup that are performing the rounds on social media, there is an essential message from Dr Swaminathan: “Countries like the UK that have had better vaccination coverage are hoping that the cases of hospitalisation and deaths will not rise. But this is not a given. Only a few countries are managing to keep the virus under good control. There are still nearly 10,000 deaths each day globally.”
Central to the present phase is the delta variant. “It is so transmissible that it requires even greater vigil to ensure it stays under control. The moment, mobility restrictions are lifted, economies open up and social mixing increases, cases will rise. This process is aided by laxity in abiding by the safety measures such as masking and maintaining physical distancing.”
Therefore, the essential focus, she maintains, demands to be on testing and surveillance mainly because “the moment there is an uptick, restrictions or targeted lockdowns have to be imposed. These are all important for India at the moment as there are signs of plateauing in the number of new cases each day and in the vaccination rate (the new cases are down from a frightening 400,000 new cases a day to around 42,000 today and the rate of vaccination at around 4 million doses a day). In fact, some experts have also raised concerns around overcoming vaccine shortages, which is hampering the vaccination process. For instance, the Mumbai Miunicipal Corporation’s vaccination centres have remained closed since Friday, July 9th and are to reopen on Monday, July 12th.
India, the doctor reminds, being such a huge country (with its sub-national patterns), there could be an uptick in some pockets and it could reverse a broader declining trend.” For instance, the caseload trends in Kerala and Maharashtra that are seeing a key share of the present caseload.
Cannot Risk Vaccine-resistant Variant
The mantra in terms of priorities are also pretty clear. She says, “we need to continue to invest in our healthcare system, and keep up the surveillance, cluster investigations and on building the healthcare cadre needed for an ever-expanding vaccination coverage.” Emphasising that “the time to act is now because we do not want to be in a situation where we end up with a variant that is resistant to the vaccines. That would mean starting the process all over again with a new virus. Fortunately, all the vaccines are still working well against severe disease caused by the virus, including the variants, but this may not last.”
On Covaxin
As for covaxin, she says, “the Phase-3 trial data looks good with protection against the variants too. Now, once the complete documentation is submitted by the company to the WHO, an independent committee will evaluate (its listing for emergency use) and look at not just efficacy and safety but also aspects relating to manufacturing and quality.” This method, she says, must in all ordinarily take in between 4 to six weeks from the time the full documentation is accomplished, and that component of submission by the corporation, appears to be at present on at the moment.”